NMRA Neumora Therapeutics, Inc. Insider Trading

VC-backed insider ARCH Venture Partners XII bought 1,915,700 shares ($5.0M) at $2.61; 5 of 5 prior NMRA buys well-timed at 90d; cluster buy.

ARCH Venture Partners XII, a 10% owner, purchased 1,915,700 shares (1.92M shares) for $5.0M on 2025-10-27, raising holdings by 46.4% to 6,046,907 shares (6.05M shares). This is notable in context of the insider's trading history at NMRA: all 5 prior purchases (November 2023) were well-timed, with 90-day returns ranging from +48.5% to +61.2%. The insider's cross-ticker track record shows a 100.00% 90-day win rate across 20 prior buys with an average 90d return of +41.6%. Additionally, 2 other insiders bought within the past 14 days, forming a cluster-buy pattern. However, fundamentals remain challenged: the company reported net income of $-52,731,000.00 ($-52.7M) and remains unprofitable. Current price of $2.50 sits 81.7% below the 52-week high of $13.64, though the stock has recovered +42.0% over the past 30 days.

ARCH Venture Partners X bought 1,915,700 shares of NMRA at $2.61 for $5.0M, raising stake to 6,046,907 shares; stock down 81.7% from $13.64 high.

ARCH Venture Partners X, a 10% owner, purchased 1,915,700 shares (1.92M shares) at $2.61 on 2025-10-27 for $5.0M, increasing holdings by 46.4% to 6,046,907 shares (6.05M shares). The transaction occurred as NMRA trades at $2.50, down 81.7% from its 52-week high of $13.64, despite a recent +42.0% 30-day recovery. Prior trades by this investor at NMRA—two buys on 2023-09-19—both posted negative 90-day returns (-13.6%), indicating poor historical timing at this ticker. The company reported a net loss of $52,731,000 ($-52.7M) for its most recent full fiscal year, underlining ongoing cash burn. A cluster buy pattern is present, with 2 other insiders also acquiring shares within the past 14 days, which provides some incremental validation, though the persistence of fundamental unprofitability and the shareholder's own historical execution challenges at this ticker remain material considerations.

Director Burow buys 1,915,700 shares of NMRA at $2.61 for $5.0M, boosting stake 46.4%; stock down 81.7% from $13.64 high but up 42.0% in 30 days.

Kristina Burow, a Director, purchased 1,915,700 shares at $2.61 on 2025-10-27 for a total of $5,000,000, increasing her holdings from 4,131,207 to 6,046,907 shares (a 46.4% increase in stake). This represents a substantial personal capital commitment at a deeply depressed valuation—the stock currently trades at $2.50, down 81.7% from its 52-week high of $13.64. Notably, 2 other insiders also bought within the past 14 days, establishing a cluster buy pattern. Her prior 5 buys at NMRA were all well-timed at the 90-day mark with returns ranging from +48.5% to +61.2%, and her cross-ticker track record shows an 88.89% 90-day win rate, though the company itself reported negative net income of $-52,731,000 for the most recent full fiscal year. The recent 30-day and 90-day price rallies (+42.0% and +27.6% respectively) follow this accumulation pattern, warranting close examination of what catalysts or operational developments may be signaling to insiders at this stage.

CFO Joshua Pinto sold 84,307 shares (35.3% of holdings) at $11.67 avg; NMRA unprofitable with -$58.7M net income

Joshua Pinto, CFO of Neumora Therapeutics, executed 3 separate sales totaling 84,307 shares for $984,061.15 over three trading days (August 22-26), reducing his holdings by 35.3% from 238,965 shares to 154,658 shares. The transactions occurred at prices ($11.63, $11.59, $11.78) very close to the current price of $11.71 and near the 90-day uptick of +23.1%, yet well below the 52-week high of $19.76. The sale by the CFO is material in scale, but its signal is complicated: the company is unprofitable (net income of -$58.7M in the most recent full fiscal year), which might ordinarily suggest leadership concern; however, without information on whether this sale was discretionary or scheduled under a pre-established plan, the narrative remains descriptive rather than explanatory of intent.